Mimix Biotherapeutics is a biomedical company based in Bienne, Switzerland. With over 10 years of research and development, they have developed a groundbreaking tissue production technology called Sound Induced Morphogenesis. This innovative platform has the potential to revolutionize tissue engineering by addressing the challenges of vascularization and high cell quantities.

Their lead product, FastSkin®, is currently in development and focuses on personalized medicine for complex wound care. Mimix Biotherapeutics is also interested in exploring other areas such as regenerative medicine (neuroscience, cardiovascular, orthopaedics), drug development, cellular agriculture (clean meat), process technology, and performance materials. They actively seek strategic discovery partnerships through collaborations with industry and academia.

Led by an experienced Board of Directors and a dedicated leadership team, including CEO Marc Thurner and CTO Andreas Scheidegger, Mimix Biotherapeutics is at the forefront of the bio fabrication revolution. Their platform combines the benefits of classical bioprinting, upgraded to a new dimension. It is poised to address some of humanity's greatest healthcare challenges.

Take a step into the future of regenerative medicine with Mimix Biotherapeutics